QCLS · CIK 0001321834 · operating
Q/C Technologies, Inc. is a clinical-stage pharmaceutical company developing therapeutic platforms targeting autoimmune and neurological conditions. The company's primary candidate is Isomyosamine, a small-molecule therapeutic designed to regulate the immunometabolic system for treatment of autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, and sarcopenia. Additionally, the company is developing Supera-CBD, a synthetic cannabidiol analog intended for epilepsy, pain management, and anxiety or depression-related disorders.
The company maintains a strategic research alliance with the DADA2 Foundation focused on understanding and treating DADA2, a rare inflammatory disease characterized by adenosine deaminase 2 deficiency. Q/C Technologies operates as a pre-commercial entity with no disclosed revenue streams, reflecting its clinical-stage status.
The company is incorporated in Delaware and headquartered in New York, New York, with minimal employee count at two full-time staff members. As a Nasdaq-listed entity, Q/C Technologies operates at an early development phase with limited scale. The company was founded in 2014 and underwent a name change from TNF Pharmaceuticals, Inc. in September 2025.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-11.15 | $-11.15 | -109.2% | |
| 2023 | $-5.33 | $-5.33 | -1266.7% | |
| 2022 | — | $-0.39 | — | |
| 2021 | — | — | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — | |
| 2018 | — | — | — | |
| 2017 | — | — | — | |
| 2016 | — | — | — | |
| 2015 | — | — | — | |
| 2014 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-04-11 | 0001641172-25-003814 | SEC ↗ |
| 2023-12-31 | 2024-04-01 | 0001493152-24-012533 | SEC ↗ |
| 2022-12-31 | 2023-03-31 | 0001493152-23-010384 | SEC ↗ |
| 2021-12-31 | 2022-03-31 | 0001493152-22-008546 | SEC ↗ |
| 2020-12-31 | 2021-03-01 | 0001493152-21-005129 | SEC ↗ |
| 2019-12-31 | 2020-03-25 | 0001493152-20-004650 | SEC ↗ |
| 2018-12-31 | 2019-04-01 | 0001493152-19-004590 | SEC ↗ |
| 2017-12-31 | 2018-04-03 | 0001493152-18-004626 | SEC ↗ |
| 2016-12-31 | 2017-04-11 | 0001493152-17-003722 | SEC ↗ |
| 2015-12-31 | 2016-03-30 | 0001493152-16-008364 | SEC ↗ |
| 2014-12-31 | 2015-03-23 | 0001493152-15-000954 | SEC ↗ |
| 2013-12-31 | 2014-03-28 | 0001144204-14-018497 | SEC ↗ |